DURECT Corporation

NasdaqCM:DRRX Voorraadrapport

Marktkapitalisatie: US$41.6m

DURECT Toekomstige groei

Future criteriumcontroles 2/6

DURECT is forecast to grow earnings and revenue by 33.2% and 56% per annum respectively while EPS is expected to grow by 32.6% per annum.

Belangrijke informatie

33.2%

Groei van de winst

32.6%

Groei van de winst per aandeel

Pharmaceuticals winstgroei23.7%
Inkomstengroei56.0%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt25 Sep 2024

Recente toekomstige groei-updates

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 10
DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Aug 08
Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Durect names ex-RBC Capital Markets executive as CFO

Jul 05

Is DURECT (NASDAQ:DRRX) A Risky Investment?

May 12
Is DURECT (NASDAQ:DRRX) A Risky Investment?

DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be

Mar 14
DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 10
DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Jan 08
Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Aug 05
Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Durect (DRRX) Investor Presentation - Slideshow

May 06

Durect EPS misses by $0.01, misses on revenue

May 04

DURECT prices ~$43M stock offering

Feb 04

DURECT surges after FDA approval for Posimir

Feb 02

Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.

Dec 16

DURECT (DRRX) Investor Presentation - Slideshow

Oct 31

Winst- en omzetgroeiprognoses

NasdaqCM:DRRX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202623-38N/AN/A1
12/31/20258-38N/AN/A2
12/31/20248-26N/AN/A3
6/30/20248-16-26-26N/A
3/31/20248-23-32-32N/A
12/31/20239-28-34-34N/A
9/30/20239-37-35-34N/A
6/30/202319-36-29-29N/A
3/31/202319-36-30-30N/A
12/31/202219-35-26-26N/A
9/30/202223-32-29-29N/A
6/30/202213-39-34-34N/A
3/31/202214-37-32-32N/A
12/31/202114-36-38-37N/A
9/30/20219-38-35-35N/A
6/30/20219-37-36-36N/A
3/31/202131-14-37-37N/A
12/31/202030-14-39-39N/A
9/30/202034-11-27-26N/A
6/30/202043-311N/A
3/31/202023-2444N/A
12/31/201925-211111N/A
9/30/201923-2411N/A
6/30/201920-24-19-19N/A
3/31/201919-24-19-19N/A
12/31/201815-25-20-20N/A
9/30/201834-10-21-21N/A
6/30/201835-1-17-17N/A
3/31/201836-4N/A1N/A
12/31/201737-4N/A-1N/A
9/30/201721-21N/A-1N/A
6/30/201716-36N/A-10N/A
3/31/201715-35N/A-30N/A
12/31/201614-35N/A-27N/A
9/30/201616-32N/A-26N/A
6/30/201617-29N/A-25N/A
3/31/201618-26N/A-22N/A
12/31/201519-23N/A-21N/A
9/30/201518-23N/A-17N/A
6/30/201518-23N/A-17N/A
3/31/201518-23N/A-17N/A
12/31/201419-22N/A-15N/A
9/30/201419-21N/A-15N/A
6/30/201418-20N/A-15N/A
3/31/201417-20N/A-15N/A
12/31/201315-21N/A-15N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: DRRX is forecast to remain unprofitable over the next 3 years.

Winst versus markt: DRRX is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: DRRX is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: DRRX's revenue (56% per year) is forecast to grow faster than the US market (8.9% per year).

Hoge groei-inkomsten: DRRX's revenue (56% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if DRRX's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven